Overview
A biopharmaceutical company recently completed quantitative segmentation and analytics within the respiratory market. While this work successfully categorized pulmonologists based on their prescribing volume and brand selection, it left a critical question unanswered.
The data identified two distinct physician behaviors regarding Brand X:
Brand X Loyalists: Pulmonologists who demonstrated a strong belief in the biologic’s efficacy and prescribed it confidently to appropriate patients.
Brand X Hesitant: Pulmonologists who showed clinical hesitation, limited utilization, or entrenched preferences for competing biologics.
While the quantitative data mapped what these segments were doing, it could not explain why their behaviors diverged. CH1 Research designed a qualitative, behavioral-science-driven study to explore the beliefs, clinical reasoning, and emotional drivers shaping Brand X prescribing behavior.
Challenge & Objectives
The core challenge was to look beyond surface-level clinical metrics and map the cognitive frameworks influencing respiratory prescribing habits. The study was structured around three key objectives:
Decode Physician Mindsets:
Uncover the underlying belief systems, attitudes, and cognitive frameworks that differentiate Brand X advocates from physicians with split brand usage. The aim was to understand how each group conceptualized the brand's role through their clinical narratives and real-world prescribing experiences.
Identify Drivers and Barriers to Advocacy:
Pinpoint what fuels strong brand advocacy, including specific clinical experiences, efficacy perceptions, patient outcomes, and emotional or rational reinforcements, while identifying the specific barriers holding hesitant physicians back.
Define Playbook Needs:
Identify the strategic elements required for an "advocacy playbook." This involved mapping the specific thoughts, experiences, and behavioral triggers that shift a physician toward an advocate mindset, while pinpointing the strategic cues—both conceptual and clinical—needed to strengthen desired beliefs and disrupt existing barriers.
The Solution
To uncover the deeper drivers of physician behavior, CH1 Research implemented a qualitative methodology combining deep clinical interviews with behavioral science techniques. This approach allowed researchers to evaluate the decision-making heuristics, or mental shortcuts, that pulmonologists use during real-world patient evaluations.
By structuring discussions around physician clinical narratives, patient journey mapping, and conceptual framing exercises, the team analyzed how similar clinical information was being interpreted through different cognitive lenses.
Results & Findings
The research challenged the client’s assumptions about what was limiting Brand X adoption. While the brand team expected barriers such as access, reimbursement, or efficacy concerns, the findings showed that the more meaningful barriers were rooted in physician mindsets, treatment heuristics, and how Brand X was classified within respiratory treatment pathways.
The study uncovered a critical perception gap, revealing two distinct decision-making archetypes:
Systemic Thinkers: Processed clinical choices through mechanism-driven factors. They viewed Brand X as a therapy capable of addressing complex, multi-pathway inflammatory drivers, making them more likely to advocate for its use with appropriate patients.
Algorithmic Reactors: Relied heavily on established, biomarker-based treatment heuristics. They often categorized Brand X as a narrower option reserved for patients who did not clearly fit traditional treatment pathways.
Key Discoveries
The Power of Heuristics: Pulmonologists were not evaluating Brand X purely on objective clinical data. Instead, established treatment shortcuts often overrode the consideration of Brand X, even when physicians explicitly acknowledged its clinical value during the interview.
Information Gaps: Prescribing confidence was constrained by limited awareness of newer clinical evidence and relevant indications, causing some hesitant physicians to rely on outdated classifications.
The Impact of Framing: The specific language used to describe Brand X's mechanism of action influenced how physicians defined appropriate patient fit. Subtle nuances in communication led some physicians to misclassify the drug or view it more narrowly than intended.
Access Was Not the Problem: Among participating physicians, access and reimbursement did not emerge as major barriers, helping confirm that the client's core challenge was more conceptual than administrative.
Predictive Decision Archetypes: Formulated two distinct mindsets that helped the client understand physician behavior based on clinical philosophy rather than prescribing volume alone.
Correction of Perception Gaps: Pinpointed how Brand X’s mechanism of action was being misunderstood or narrowly classified, providing a clear starting point for correcting clinical misclassifications.
Refined Communication Strategies: Offered specific guidance on how to adjust language and framing to address clinical uncertainty and disrupt unhelpful mental shortcuts.
A Blueprint for Advocacy: Generated a strategic framework to help move hesitant physicians toward greater confidence, stronger consideration, and increased advocacy for Brand X within respiratory management.
Conclusion
CH1 Research helped bridge the gap between quantitative market data and strategic execution by revealing how pulmonologists evaluated respiratory biologic treatment options.
The study showed that strengthening Brand X adoption required addressing the cognitive frameworks through which physicians interpreted clinical data.
Civicom MRS • June 16, 2026
